PROKIDNEY CORP.

Overview

Compare with Compass Therapeutics, Inc., ImageneBio, Inc. or Avalanche Biotechnologies, or pick any stock.

• TickerPROK on Nasdaq¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersWinston-Salem, North Carolina¹
• Incorporated inCayman Islands³
• Business address2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, Nc 27103³
• Filer category, Emerging growth company³

See how the biggest companies compare on our leaderboards

We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease (“CKD”) and diabetes. Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure to the preservation of kidney function. Our lead product candidate, rilparencel, is the only cell therapy in Phase 3 clinical study for the treatment of advanced CKD and type 2 diabetes. Rilparencel is a product that includes autologous Selected Renal Cells (“SRC”) prepared from a patient’s own (autologous) kidney cells. The SRC are formulated as rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure. Because rilparencel is a personalized product composed of cells prepared from a patient’s own …⁵ From its latest annual report

Corporate structure

PROKIDNEY CORP. sits at the top of its group. 6 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PROKIDNEY CORP. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We own two buildings in Winston-Salem, North Carolina, portions of which buildings we previously occupied pursuant to real estate leases. The two buildings represent total usable space of approximately 180,000 square feet. The portion of the buildings we currently occupy are used for office, manufacturing and research space. The remaining portion of these buildings are leased by us to third parties under lease agreements that expire between 2026 and 2029.

We have also leased approximately 14,700 square feet of office and warehouse space in Winston-Salem under leases that expire in 2027. Additionally, we have leased a total of approximately 16,300 square feet of office and laboratory space in the Research Triangle Park area of North Carolina under leases expiring in July 2027 and July 2031, respectively. Finally, we have leased approximately 7,400 square feet of office space in Boston, Massachusetts under a lease that expires in January 2029.

Item 2 of the 10-K filed Mar 18, 2026.⁵

Leadership

Who has led PROKIDNEY CORP., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerBruce Culleton Dec 5, 2023 to now¹³
• Chief executive officerTimothy Bertram Jul 13, 2022 to Jan 18, 2023¹⁴
• Chief financial officerJames Coulston Jul 13, 2022 to now¹⁵
• Chief financial officerJames Ryans Jun 29, 2021 to Jun 29, 2021¹⁶
• Chief operating officerDeepak Jain Jul 13, 2022 to Jan 18, 2023¹⁷

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• ProKidney Acquisition Company II, LLC Delaware⁴
• ProKidney Acquisition Company, LLC Delaware⁴
• ProKidney Holdings, LLC Delaware⁴
• ProKidney IPCo, LLC Delaware⁴
• ProKidney Intermediate Holdings, LLC Delaware⁴
• ProKidney, LLC Delaware⁴

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• Social Capital Suvretta Holdings Corp. IIIApr 21, 2021 to Jul 11, 2022³

Timeline

1. Aug 10, 20268-K Results of operations³⁵
2. May 29, 20268-K Shareholder vote³⁶
3. May 15, 20268-K Results of operations; Regulation FD disclosure; Other events³⁷
4. Mar 18, 20268-K Results of operations³⁸
5. Feb 2, 20268-K Regulation FD disclosure; Other events³⁹
6. Jan 12, 20268-K Regulation FD disclosure⁴⁰
7. Nov 10, 20258-K Results of operations⁴¹
8. Oct 17, 20258-K Entered a material agreement⁴²
9. Aug 12, 20258-K Results of operations⁴³
10. Jul 15, 20258-K Regulation FD disclosure; Other events⁴⁴
11. Jul 14, 20258-K Entered a material agreement; Ended a material agreement; Other events⁴⁵
12. Jul 8, 20258-K Regulation FD disclosure⁴⁶
13. Dec 5, 2023New chief executive Bruce Culleton becomes CEO¹³
14. Jul 13, 2022New chief executive Timothy Bertram becomes CEO¹⁴

Calendar

Coming up

1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.12) a share, on Nov 10, 2025.⁴⁷

When it reported results

1. Aug 10, 2026Reported quarterly or annual results³⁵
2. May 15, 2026Reported quarterly or annual results³⁷
3. Mar 18, 2026Reported quarterly or annual results³⁸
4. Nov 10, 2025Reported quarterly or annual results⁴¹
5. Aug 12, 2025Reported quarterly or annual results⁴³
6. May 12, 2025Reported quarterly or annual results⁴⁸
7. Mar 17, 2025Reported quarterly or annual results⁴⁹
8. Nov 12, 2024Reported quarterly or annual results⁵⁰

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

371 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 67 major events, 144 insider forms, 37 large holders, 102 other. The latest 20:

1. Aug 20, 20264 EDGAR
2. Aug 18, 2026144 EDGAR
3. Aug 18, 2026144 EDGAR
4. Aug 12, 2026SCHEDULE 13G/A EDGAR
5. Aug 10, 20268-K EDGAR
6. Aug 10, 202610-Q EDGAR
7. Aug 6, 20264 EDGAR
8. Jul 6, 20264 EDGAR
9. Jun 15, 20264 EDGAR
10. Jun 10, 20263 EDGAR
11. May 29, 20264 EDGAR
12. May 29, 20264 EDGAR
13. May 29, 20264 EDGAR
14. May 29, 20264 EDGAR
15. May 29, 20264 EDGAR
16. May 29, 20264 EDGAR
17. May 29, 20264 EDGAR
18. May 29, 20268-K EDGAR
19. May 15, 20268-K EDGAR
20. May 15, 202610-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

66 open-market trades by officers, directors and large owners since October 2021: 17 buys and 49 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Morgan StanleySCHEDULE 13G/A, 8 filings Sep 12, 2022 to Aug 12, 2026⁵¹
• Empresarial De Capitales S.a. De C.v. ControlSCHEDULE 13D/A, 3 filings Jul 22, 2022 to Apr 30, 2026⁵²
• BlackRockSCHEDULE 13G/A, 3 filings Oct 18, 2024 to Jul 17, 2025⁵³
• Tolerantia, LLCSCHEDULE 13D/A, 6 filings Jul 22, 2022 to Jun 5, 2025⁵⁴
• MONTANOVA CAPITAL, LLCSC 13G/A, 4 filings Jul 22, 2022 to Oct 22, 2024⁵⁵
• Chamath PalihapitiyaSC 13D/A, 6 filings Jul 20, 2022 to Nov 20, 2023⁵⁶
• Sculptor Capital LPSC 13G/A, 2 filings Dec 29, 2021 to Feb 14, 2023⁵⁷
• INTEGRATED CORE STRATEGIES (US) LLCSC 13G/A, 2 filings Jan 25, 2022 to Feb 10, 2023⁵⁸
• ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 1 filing Feb 9, 2023⁵⁹
• SCS Sponsor III LLCSC 13G/A, 2 filings Feb 9, 2022 to Jul 21, 2022⁶⁰

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 69. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PROKIDNEY CORP. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARPROKIDNEY CORP.¹
• CIK0001850270
• Employer ID (EIN)98-1586514⁵
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC 27103¹
• Phone336-999-7028¹
• Shares outstanding141,942,905 Common Class A shares; 159,973,180 Common Class B shares as of Mar 18, 2026⁵
• Public float$58.9M as of Jun 30, 2025⁵
• AuditorErnst & Young LLP, Atlanta, Georgia, United States PCAOB ID 42; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceApr 21, 2021¹
• Filings397 in all: 4 (124), 8-K (62), 3 (26), DEFA14A (22), 10-Q (16), 424B3 (15), 144 (11), SC 13G/A (11)¹
  All 42 form types

  CORRESP (9), EFFECT (9), SC 13D/A (8), SC 13G (8), UPLOAD (7), 8-K/A (6), 10-K (5), POS AM (5), S-8 (5), 424B5 (4), ARS (4), S-8 POS (4), SC 13D (4), SCHEDULE 13G/A (4), DEF 14A (3), S-1/A (3), SCHEDULE 13D/A (3), PRER14A (2), S-1 (2), 10-K/A (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K12B (1), 8-K12B/A (1), CERT (1), DEFM14A (1), DEL AM (1), DRS (1), PREM14A (1), S-1MEF (1), S-3 (1), S-4 (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 18, 2026
  Quarterly report (10-Q) Aug 10, 2026
  Proxy statement (DEF 14A) Apr 17, 2026
  Latest 8-K (8-K) Aug 10, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 18, 2026 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks PROKIDNEY CORP. names in Item 1A of its 10-K filed Mar 18, 2026: 72 risks under these headings, as written.⁵

• Risks Related to Our Financial Position and Need for Additional Capital
• We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.
• We will continue to require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs, future commercialization efforts or other operations.
• Risks Related to Research and Development of Rilparencel and Our Future Product Candidates
• We have a limited operating history and have not generated any revenue to date, and may never become profitable.
• The market for biologics and for the treatment of kidney disease is highly competitive. If we fail to effectively compete, our business, financial condition and operating results will suffer.
• Our business is highly dependent on the success of our lead product candidate, rilparencel, as well as any other future product candidates that we may advance into clinical development. Rilparencel and our future product candidates will require significant additional clinical development and funding before we may be able to seek regulatory approval for and launch a product commercially.
• Rilparencel is based on a novel technology, which makes it difficult to predict the time and cost of product development and of subsequently obtaining regulatory approval.
• Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of nonclinical studies, previous clinical trials, or interim results of ongoing clinical trials of rilparencel and any of our future product candidates may not be predictive of future results. Further, we may encounter substantial delays in completing the development of rilparencel and any of our future product candidates.
• Any topline data or interim analyses from our nonclinical studies and clinical trials that may be announced or published from time to time may change as more data becomes available and will remain subject to audit and verification procedures that could result in material changes in the final data.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for rilparencel, our lead product candidate, or any of our future product candidates, our business may be materially and adversely affected.
• Our nonclinical studies and clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of rilparencel or our future product candidates, or serious adverse or unacceptable side effects may be identified during the development of rilparencel or any of our future product candidates, which could prevent, delay or limit the scope of regulatory approval of rilparencel or any of our future product candidates, limit their commercialization, increase our costs or necessitate the abandonment or limitation of the development of rilparencel or our future product candidates.

Legal proceedings

From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.⁵